Clinical Trial

Tarlatamab for SCLC Brain Metastases

Name: Tarlatamab for SCLC Brain Metastases — clinical trial record (NCT07402343)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: T-BRAIN

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-01

Trial Details

NCT Number	NCT07402343
Lead Sponsor	Maastricht University Medical Center Collaborators: The Netherlands Cancer Institute, Erasmus Medical Center, University Medical Center Groningen
Conditions	Small Cell Lung Cancer, Brain Metastases, Adult
Enrollment	35 participants
Start Date	2026-08
Primary Completion	2029-02 (estimated)
Study Completion	2030-02 (estimated)
Updated on ClinicalTrials.gov	2026-07-31